KR101054237B1 - 플리반세린 다형체 α를 함유하는 신규한 약제학적 조성물 - Google Patents

플리반세린 다형체 α를 함유하는 신규한 약제학적 조성물 Download PDF

Info

Publication number
KR101054237B1
KR101054237B1 KR1020047018741A KR20047018741A KR101054237B1 KR 101054237 B1 KR101054237 B1 KR 101054237B1 KR 1020047018741 A KR1020047018741 A KR 1020047018741A KR 20047018741 A KR20047018741 A KR 20047018741A KR 101054237 B1 KR101054237 B1 KR 101054237B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
core
mixtures
coating
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047018741A
Other languages
English (en)
Korean (ko)
Other versions
KR20040111668A (ko
Inventor
프리들토마스
라트케구이도베른하르트에드문트
Original Assignee
베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 filed Critical 베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Publication of KR20040111668A publication Critical patent/KR20040111668A/ko
Application granted granted Critical
Publication of KR101054237B1 publication Critical patent/KR101054237B1/ko
Assigned to 스프라우트 파마슈티칼스, 인코포레이티드 reassignment 스프라우트 파마슈티칼스, 인코포레이티드 권리의 전부이전등록 Assignors: 베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020047018741A 2002-05-22 2003-05-19 플리반세린 다형체 α를 함유하는 신규한 약제학적 조성물 Expired - Lifetime KR101054237B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
EP02011224.9 2002-05-22
PCT/EP2003/005226 WO2003097058A1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (2)

Publication Number Publication Date
KR20040111668A KR20040111668A (ko) 2004-12-31
KR101054237B1 true KR101054237B1 (ko) 2011-08-08

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047018741A Expired - Lifetime KR101054237B1 (ko) 2002-05-22 2003-05-19 플리반세린 다형체 α를 함유하는 신규한 약제학적 조성물

Country Status (25)

Country Link
EP (1) EP1511489B1 (https=)
JP (1) JP3919788B2 (https=)
KR (1) KR101054237B1 (https=)
CN (3) CN102240289A (https=)
AT (1) ATE499939T1 (https=)
BR (1) BRPI0311189B8 (https=)
CA (1) CA2483597C (https=)
CY (1) CY1111470T1 (https=)
DE (1) DE60336225D1 (https=)
DK (1) DK1511489T3 (https=)
EA (1) EA007185B1 (https=)
EC (1) ECSP045493A (https=)
ES (1) ES2361994T3 (https=)
HR (1) HRP20041092B1 (https=)
IL (1) IL164440A0 (https=)
ME (1) MEP55308A (https=)
MX (1) MXPA04011487A (https=)
NO (1) NO329414B1 (https=)
NZ (1) NZ537253A (https=)
PL (1) PL211062B1 (https=)
RS (1) RS51718B (https=)
SI (1) SI1511489T1 (https=)
UA (1) UA80135C2 (https=)
WO (1) WO2003097058A1 (https=)
ZA (1) ZA200408151B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists
KR20040023704A (ko) * 2001-08-02 2004-03-18 비다켐 에스. 피. 에이. 플리반세린의 안정한 다형체, 이의 기술적 제조 방법 및약제 제조시 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists
KR20040023704A (ko) * 2001-08-02 2004-03-18 비다켐 에스. 피. 에이. 플리반세린의 안정한 다형체, 이의 기술적 제조 방법 및약제 제조시 이의 용도

Also Published As

Publication number Publication date
BR0311189A (pt) 2005-02-22
BRPI0311189B8 (pt) 2021-05-25
JP3919788B2 (ja) 2007-05-30
PL211062B1 (pl) 2012-04-30
ES2361994T3 (es) 2011-06-27
EA007185B1 (ru) 2006-08-25
UA80135C2 (en) 2007-08-27
SI1511489T1 (sl) 2011-06-30
IL164440A0 (en) 2005-12-18
JP2005530787A (ja) 2005-10-13
NZ537253A (en) 2007-09-28
KR20040111668A (ko) 2004-12-31
MEP55308A (en) 2011-05-10
EP1511489A1 (en) 2005-03-09
DK1511489T3 (da) 2011-05-02
PL372457A1 (en) 2005-07-25
EP1511489B1 (en) 2011-03-02
CN1655789A (zh) 2005-08-17
CN101002780A (zh) 2007-07-25
ECSP045493A (es) 2005-03-10
WO2003097058A1 (en) 2003-11-27
NO329414B1 (no) 2010-10-18
CA2483597A1 (en) 2003-11-27
NO20044547L (no) 2004-12-17
ATE499939T1 (de) 2011-03-15
HRP20041092A2 (en) 2005-06-30
AU2003240672A1 (en) 2003-12-02
RS98704A (sr) 2006-12-15
DE60336225D1 (de) 2011-04-14
CN102240289A (zh) 2011-11-16
CA2483597C (en) 2010-02-09
EA200401515A1 (ru) 2005-06-30
RS51718B (sr) 2011-10-31
ZA200408151B (en) 2006-06-28
BRPI0311189B1 (pt) 2019-04-09
MXPA04011487A (es) 2005-02-14
HRP20041092B1 (hr) 2013-05-31
CY1111470T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
KR101054237B1 (ko) 플리반세린 다형체 α를 함유하는 신규한 약제학적 조성물
US20070196473A1 (en) Pharmaceutical compositions containing flibanserin
US7553500B2 (en) Pharmaceutical composition having uniform drug distribution and potency
EP2964200B1 (en) Formulations of organic compounds
HUP9902769A2 (hu) Eprosartan-dihidrát, valamint eljárás a vegyület előállítására és formálására
IL305235A (en) Pharmaceutical dosage forms containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)- 32H -6-aza-3(1,4)-pyridine -1 (1)-[3,2,1]triazol-2-(2,1),7(1)-dibenzeneheptapane-74-carboxamide
US20030190352A1 (en) Compositions of venlafaxine base
AU2003240672B2 (en) New pharmaceutical compositions containing flibanserin polymorph A
US20230119355A1 (en) Pharmaceutical compositions of a kinase inhibitor
JP2022539142A (ja) ダロルタミドの医薬組成物
HK1104975A (en) New pharmaceutical compositions containing flibanserin polymorph a
CA2545513C (en) Solid pharmaceutical preparation form
US20230310327A1 (en) Pharmaceutical compositions comprising ribociclib
HK1080739A (en) New pharmaceutical compositions containing flibanserin polymorph a
HK1212244B (en) Formulations of organic compounds
CZ20001487A3 (cs) Prostředky obsahující činidla snižující hladinu tuků

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080519

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100827

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110627

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110729

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110801

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150716

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150716

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160721

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160721

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170721

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170721

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180719

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180719

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190718

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190718

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200716

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20220701

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20231119

Termination category: Expiration of duration